Boots is one of Britain’s most enduring businesses, with a rich heritage, a trusted name and a

As the Weston family finalized a deal to acquire the prominent beauty and high-street pharmacy chain for $8.9bn (£6.74bn), Wittington Investments chair Galen Weston remarked that Boots holds an essential place in daily life across Ireland and the UK, backed by a trusted identity and a storied history as one of Britain’s most resilient enterprises.

Weston Family Acquires Nottingham-Headquartered Chain

Wittington Investments, the holding company that controls Canada’s Loblaws grocery chain and Shoppers Drug Mart pharmacy outlets, will take ownership of Boots’ UK and Irish retail operations, its opticians chain, the No7 beauty brand, and a franchise arm in Thailand. The transaction is also being backed by the investment firm Fairfax, which owns The Sporting Life Group and Simba Sleep parent company Sleep Country.

The deal marks the exit of Boots’ long-term backer Stefano Pessina and his latest financial partner, Sycamore Partners. Pessina, who took Boots private alongside investment firm KKR in 2007, will retain ownership of the Farmacias Benavides pharmacy chain in Mexico and Alliance Healthcare Deutschland in Germany. US pharmacy group Walgreens previously put Boots up for sale in 2022 with a £10bn price tag before dropping plans due to fundraising struggles among prospective buyers like Reliance Industries, Apollo Global Management, and TDR Capital. A planned stock market floatation was subsequently dropped in 2024.

New Owners Plan to Expand Healthcare Services

The buyout arrives as pharmacies face increasing demands to prescribe medications and health services in order to ease pressure on hospitals and GP surgeries. Retail analyst Catherine Shuttleworth noted that shoppers will likely see an improved shopping experience over time as the new owners inject fresh investment into health and beauty, which she described as a massive area for growth.

New owners plan to expand Boots’ healthcare services, building on its roots as a Nottingham apothecary founded by John Boot in 1849 as an affordable alternative to traditional medicines. The retailer already offers prescriptions, vaccinations, and expanded weight loss drug services in-store. However, the chain faces steep competition from online influencer advertisements, digital beauty retailers, and traditional rivals such as Superdrug. Retail competition intensified further as Marks & Spencer announced plans to replace a hundred of its own beauty departments with Sephora next year.

Regulatory Approval and Completion Timeline for 2027

The acquisition remains subject to regulatory approval and is expected to close formally in the first quarter of 2027. Providing his perspective on the shift, Galen Weston explained that the purchasers view this as a significant chance to elevate an already strong enterprise through patient ownership, additional financial backing, and a fresh operational strategy focused on delivering exceptional customer service.

We see a meaningful opportunity to make a great business even better through stable long-term ownership, further capital investment, and the renewed operating focus required to serve customers with excellence for generations to come.

Galen Weston